Plus Therapeutics (PSTV) Competitors $1.30 +0.01 (+0.78%) (As of 11/13/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PSTV vs. IDXG, BSGM, POCI, IRIX, DRIO, MDAI, FEMY, XAIR, NRXS, and NXGLShould you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include Interpace Biosciences (IDXG), BioSig Technologies (BSGM), Precision Optics (POCI), IRIDEX (IRIX), DarioHealth (DRIO), Spectral AI (MDAI), Femasys (FEMY), Beyond Air (XAIR), NeurAxis (NRXS), and NEXGEL (NXGL). Plus Therapeutics vs. Interpace Biosciences BioSig Technologies Precision Optics IRIDEX DarioHealth Spectral AI Femasys Beyond Air NeurAxis NEXGEL Interpace Biosciences (NASDAQ:IDXG) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, community ranking, dividends, earnings, institutional ownership and analyst recommendations. Does the MarketBeat Community favor IDXG or PSTV? Interpace Biosciences received 254 more outperform votes than Plus Therapeutics when rated by MarketBeat users. Likewise, 72.83% of users gave Interpace Biosciences an outperform vote while only 61.32% of users gave Plus Therapeutics an outperform vote. CompanyUnderperformOutperformInterpace BiosciencesOutperform Votes31972.83% Underperform Votes11927.17% Plus TherapeuticsOutperform Votes6561.32% Underperform Votes4138.68% Does the media refer more to IDXG or PSTV? In the previous week, Interpace Biosciences and Interpace Biosciences both had 3 articles in the media. Plus Therapeutics' average media sentiment score of 0.47 beat Interpace Biosciences' score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Interpace Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, IDXG or PSTV? Interpace Biosciences has higher revenue and earnings than Plus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInterpace Biosciences$40.21M0.33$800KN/AN/APlus Therapeutics$4.91M1.62-$13.32M-$3.16-0.43 Do insiders & institutionals believe in IDXG or PSTV? 5.7% of Interpace Biosciences shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 5.5% of Interpace Biosciences shares are held by company insiders. Comparatively, 5.5% of Plus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer IDXG or PSTV? Plus Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 936.88%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Interpace Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Interpace Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Plus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IDXG or PSTV more profitable? Interpace Biosciences has a net margin of 10.39% compared to Plus Therapeutics' net margin of -240.15%. Plus Therapeutics' return on equity of 0.00% beat Interpace Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Interpace Biosciences10.39% -8.09% 37.14% Plus Therapeutics -240.15%N/A -127.52% Which has more risk & volatility, IDXG or PSTV? Interpace Biosciences has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. SummaryInterpace Biosciences beats Plus Therapeutics on 8 of the 15 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTV vs. The Competition Export to ExcelMetricPlus TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.97M$4.65B$5.24B$8.99BDividend YieldN/A39.52%4.99%4.03%P/E Ratio-0.4312.8686.3813.28Price / Sales1.6263.921,304.9093.85Price / CashN/A52.4538.9636.60Price / Book-4.505.666.486.02Net Income-$13.32M$13.58M$118.16M$224.96M7 Day Performance-5.58%0.06%-0.07%1.13%1 Month Performance-1.45%8.17%5.61%6.60%1 Year Performance-7.52%59.01%42.32%32.97% Plus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSTVPlus Therapeutics3.1429 of 5 stars$1.30+0.8%$14.00+976.9%-7.5%$7.67M$4.91M-0.4120Upcoming EarningsNews CoverageGap DownHigh Trading VolumeIDXGInterpace BiosciencesN/A$2.99+2.4%N/A+152.9%$13.16M$40.21M0.00152News CoverageBSGMBioSig TechnologiesN/A$1.85-6.6%N/A-44.6%$31.69M$20,000.000.0050News CoveragePositive NewsPOCIPrecision Optics1.2046 of 5 stars$4.82-0.4%N/A-21.4%$30.61M$19.10M-9.8480Upcoming EarningsShort Interest ↓Gap UpIRIXIRIDEX0.3106 of 5 stars$1.85+31.2%N/A-32.2%$30.54M$51.87M-2.76120Earnings ReportShort Interest ↓News CoverageGap UpHigh Trading VolumeDRIODarioHealth2.3261 of 5 stars$0.88+1.6%N/A-19.2%$29.97M$20.35M-0.94200Gap DownMDAISpectral AI2.86 of 5 stars$1.39+3.0%N/A-51.8%$25.73M$18.06M-2.1478Analyst RevisionFEMYFemasys2.8004 of 5 stars$1.04+1.0%N/A-15.6%$23.12M$1.07M-1.2830Earnings ReportAnalyst ForecastShort Interest ↑News CoverageGap UpXAIRBeyond Air4.5786 of 5 stars$0.49-1.5%N/A-75.9%$22.98M$1.16M-0.3570Earnings ReportNews CoverageGap UpNRXSNeurAxisN/A$3.09-2.2%N/A+23.9%$21.14M$2.46M-1.6819News CoverageNXGLNEXGEL1.7431 of 5 stars$3.20+1.6%N/A+83.1%$20.22M$4.09M-5.6110Upcoming EarningsNews CoverageHigh Trading Volume Related Companies and Tools Related Companies Interpace Biosciences Competitors BioSig Technologies Competitors Precision Optics Competitors IRIDEX Competitors DarioHealth Competitors Spectral AI Competitors Femasys Competitors Beyond Air Competitors NeurAxis Competitors NEXGEL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PSTV) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
